Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking John Paulson’s Paulson & Co...
REDMOND, Wash. and NEW YORK , May 26, 2020 /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups ...
Introduction Think about it: the world is having a health crisis and what do we do? We created the largest global collapse since 1929! And as noted in prior columns , we are now at a point where nobody wanted to go: we must continually ask: do we continue the global “lockdownȁ...
Takeda Receives FDA Approval for Brigatinib Takeda Pharmaceutical Company Limited ( TAK ) announced that the FDA has given a green signal for its ALUNBRIG (Brigatinib) in adult patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer. The lab...
The FDA approves Takeda Pharmaceutical Company's (NYSE: TAK ) Alunbrig (brigatinib) for the first-line treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer. More news on: Takeda Pharmaceutical Company Limited, Healthcare stocks...
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today anno...
Image source: The Motley Fool. TAKU GOLD CORP (NYSE: TAK) Q4 2019 Earnings Call May 13, 2020 , 3:00 p.m. ET Takashi Okubo Continue reading
– Scientific Advancements Seek to Address Therapeutic Needs in Underserved Oncology Communities, Including Rare Leukemias and NSCLCs – New Clinical Data Offer Practice-Changing Potential in Treatment of Chronic Myeloid Leukemia – 11 Takeda Oncology-Sponso...
– Approval is Based on Results of Phase 3 ECHELON-2 Trial, Which Demonstrated Treatment with ADCETRIS Plus CHP (cyclophosphamide, doxorubicin, prednisone) Resulted in Significant Improvement in Progression-Free Survival Compared with a Standard of Care – Takeda Pharmace...
Takeda Pharmaceutical Company Limited (TKPHF) Q4 2019 Earnings Conference Call May 13, 2020, 08:30 AM ET Company Participants Takashi Okubo - IR Christophe Weber - President and CEO Andrew Plump - President of R&D Costa Saroukos - CFO Ramona Sequeira - President of USBU a...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...